Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Ambrx Biopharma Cayman, Inc.
| Metric | Ambrx Biopharma Cayman, Inc. Healthcare |
|---|---|
| Quality Score | 35 / 100 |
| Revenue (latest) | $7M |
| Net income (latest) | −$78M |
| Operating margin | −1032.2% |
| Net margin | −1053.7% |
| Return on equity | −66.2% |
| Return on assets | −53.1% |
| Return on capital (ROCE) | −58.6% |
| Debt / equity | 0.25× |
| Revenue growth (YoY) | −0.7% |
| Altman Z″ (distress) | -2.41 |
| Accruals / assets | −6.3% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.